Name : Biotinylated Human LILRB4/CD85k/ILT3 Domain 1+hinge Protein
Product Source :
Recombinant Biotinylated Human LILRB4/CD85k/ILT3 Domain 1+hinge Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. It contains Gln22-Lys123.[Accession | AAH26309.1]
Molecular Weight :
The protein has a predicted MW of 14.77 kDa. Due to glycosylation, the protein migrates to 15-20 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 90% as determined by HPLC
Formulation :
Supplied as 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution :
Storage and Stability :
Valid for 12 months from date of receipt when stored at -80°C.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Biotinylated Human LILRB4 Domain 1+hinge on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Biotinylated Human LILRB4 Domain 1+hinge is greater than 90% as determined by SEC-HPLC.
Background :
LILRB4,also known as CD85k and LIR-5, ILT3, is an approximately 60 kDa transmembrane glycoprotein that negatively regulates immune cell activation. Mature human ILT3 consists of a 238 amino acid (aa) extracellular domain with two Ig-like domains, a 21 aa transmembrane segment, and a 168 aa cytoplasmic domain with 3 immunoreceptor tyrosine-based inhibitory motifs (ITIM).LILRB4 is receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles.
Synonyms :
HM18; ILT3; ILT-3; LILRB4; LIR5; CD85K
References & Citations :
(1)Samuel J , Heyu C , Mi D , et al. A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML[J]. Molecular Therapy, 2018:S1525001618303721-.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
CD46 Protein
AQP4 Protein
Popular categories:
SMAD1
PAI-1